Effect of Bimekizumab on Patient-Reported Outcomes and Work Productivity in Patients With Psoriatic Arthritis: 1-Year Results From 2 Phase III Studies
Bimekizumab treatment resulted in sustained improvements in patient-reported symptoms, HRQOL, and work productivity up to 1 year in bDMARD-naïve and TNFi-IR patients with active PsA.
Authors
- William Tillett (ORCID: https://orcid.org/0000-0001-7531-4125)
- Barbara Ink
- M. Elaine Husni (ORCID: https://orcid.org/0000-0002-3181-4205)
- Jason Coarse
- Rajan Bajracharya (ORCID: https://orcid.org/0009-0000-7857-8783)
- Alice Bendix Gottlieb (ORCID: https://orcid.org/0000-0002-2927-8618)
- Jérémy Lambert (ORCID: https://orcid.org/0000-0002-7164-1492)
- Philip J. Mease (ORCID: https://orcid.org/0000-0002-6620-0457)
- Nikos Lyris
- Laure Gossec (ORCID: https://orcid.org/0000-0002-4528-310X)
- Dafna Gladman
Institutions
- Royal National Hospital for Rheumatic Diseases (GB)
- Cleveland Clinic (US)
- University Health Network (CA)
- Inserm (FR)
- North Carolina Institute of Medicine (US)
- Cleveland Clinic Lerner College of Medicine (US)
- Sorbonne Université (FR)
- Swedish Medical Center (US)
- Assistance Publique – Hôpitaux de Paris (FR)
- UCB Pharma (France) (FR)
- Pitié-Salpêtrière Hospital (FR)
- Institut Pierre Louis d‘Épidémiologie et de Santé Publique (FR)
- UCB Pharma (United Kingdom) (GB)
- Krembil Research Institute
- University of Bath (GB)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- The Journal of Rheumatology
- Published
- 2025-02-01
- DOI
- https://doi.org/10.3899/jrheum.2024-0923
- Citations
- 1
- Primary Topic
- Rheumatoid Arthritis Research and Therapies
- Type
- article
- Field-Weighted Citation Impact
- 1.67
Funders
- Amgen
- Eli Lilly and Company
- Pfizer
- Sanofi
- Teva Pharmaceutical Industries
- XBiotech